Curve Biosciences, a chronic disease blood-testing and monitoring company, announced $40 million in funding led by Luma Group.
Why it matters: The startup plans to begin raising a Series B round next year as it prepares for a commercial launch in 2027, CEO Ritish Patnaik tells Axios Pro.
